A Phase Ib Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Relapsed or Refractory Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Their Standard Treatment

Trial Profile

A Phase Ib Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Relapsed or Refractory Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Their Standard Treatment

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Venetoclax (Primary) ; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 28 Aug 2017 Results assessing efficacy and acceptable safety (data cut off: 19 Aug 2016) published in the Blood.
    • 25 Jun 2017 Safety and preliminary efficacy results (As of 19 Aug 2016), presented at the 22nd Congress of the European Haematology Association
    • 25 Jun 2017 Results of correlative biomarker analysis, presented at the 22nd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top